CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
The NHS is set to trial an AI-based solution that can forecast type 2 diabetes risk by analyzing …
Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
As 2024 concludes, insights from Velocity Clinical Research highlight how clinical trial operations next year will be shaped …
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
A landmark regulatory update aims to speed approvals, reduce bureaucracy, and strengthen the UK’s position as a global …